Assembly and immunological properties of Newcastle disease virus-like particles containing the respiratory syncytial virus F and G proteins.
about
Virus like particle-based vaccines against emerging infectious disease viruses.Newcastle disease virus-like particles: preparation, purification, quantification, and incorporation of foreign glycoproteinsModification of the respiratory syncytial virus f protein in virus-like particles impacts generation of B cell memory.Co-immunization with virus-like particle and DNA vaccines induces protection against respiratory syncytial virus infection and bronchiolitis.CD200R1 supports HSV-1 viral replication and licenses pro-inflammatory signaling functions of TLR2.Additive protection induced by mixed virus-like particles presenting respiratory syncytial virus fusion or attachment glycoproteinsVirus-like nanoparticle and DNA vaccination confers protection against respiratory syncytial virus by modulating innate and adaptive immune cells.Nanoparticle vaccines encompassing the respiratory syncytial virus (RSV) G protein CX3C chemokine motif induce robust immunity protecting from challenge and disease.Decrease in formalin-inactivated respiratory syncytial virus (FI-RSV) enhanced disease with RSV G glycoprotein peptide immunization in BALB/c mice.Progress in understanding and controlling respiratory syncytial virus: still crazy after all these yearsMammalian Cell-Derived Respiratory Syncytial Virus-Like Particles Protect the Lower as well as the Upper Respiratory TractMurine immune responses to virus-like particle-associated pre- and postfusion forms of the respiratory syncytial virus F proteinRespiratory syncytial virus-like nanoparticle vaccination induces long-term protection without pulmonary disease by modulating cytokines and T-cells partially through alveolar macrophages.Protection conferred by virus-like particle vaccines against respiratory syncytial virus infection in mice by intranasal vaccination.Cotton rat immune responses to virus-like particles containing the pre-fusion form of respiratory syncytial virus fusion protein.Virus-Like Particle Vaccine Containing the F Protein of Respiratory Syncytial Virus Confers Protection without Pulmonary Disease by Modulating Specific Subsets of Dendritic Cells and Effector T Cells.Long-term and memory immune responses in mice against Newcastle disease virus-like particles containing respiratory syncytial virus glycoprotein ectodomainsIntranasal immunization with a helper-dependent adenoviral vector expressing the codon-optimized fusion glycoprotein of human respiratory syncytial virus elicits protective immunity in BALB/c mice.Targeting RSV with vaccines and small molecule drugs.The Respiratory Syncytial Virus Phosphoprotein, Matrix Protein, and Fusion Protein Carboxy-Terminal Domain Drive Efficient Filamentous Virus-Like Particle Formation.Recent developments with live-attenuated recombinant paramyxovirus vaccines.The role of dendritic cells in innate and adaptive immunity to respiratory syncytial virus, and implications for vaccine development.Respiratory syncytial virus: current progress in vaccine development.Advances in and the potential of vaccines for respiratory syncytial virus.Bioengineering virus-like particles as vaccines.Novel therapies and vaccines against the human respiratory syncytial virus.Recent advances in the development of subunit-based RSV vaccines.A chimeric EBV gp350/220-based VLP replicates the virion B-cell attachment mechanism and elicits long-lasting neutralizing antibodies in miceSoluble F proteins exacerbate pulmonary histopathology after vaccination upon respiratory syncytial virus challenge but not when presented on virus-like particles.The importance of RSV F protein conformation in VLPs in stimulation of neutralizing antibody titers in mice previously infected with RSV.Virus-like particle vaccines containing F or F and G proteins confer protection against respiratory syncytial virus without pulmonary inflammation in cotton rats.Experimental animal model for analyzing immunobiological responses following vaccination with formalin-inactivated respiratory syncytial virus.Influence of antigen conformation and mode of presentation on the antibody and protective responses against human respiratory syncytial virus: relevance for vaccine development.Baculovirus-expressed virus-like particle vaccine in combination with DNA encoding the fusion protein confers protection against respiratory syncytial virus.Chimeric influenza-virus-like particles containing the porcine reproductive and respiratory syndrome virus GP5 protein and the influenza virus HA and M1 proteins.Meeting report VLPNPV: Session 3: Immune responses.Do recombinant-engineered nanoparticle vaccines hold promise for the prevention of respiratory syncytial virus?Efficacy of a respiratory syncytial virus vaccine candidate in a maternal immunization model.Respiratory syncytial virus vaccine developmentProgress in respiratory virus vaccine development
P2860
Q30249025-77C36958-7A7A-4A69-B68D-D9649115B9E8Q33677863-24D11877-534F-4C2C-A519-75C38AA92F5CQ34059404-0EFE8C09-D6F6-4CF2-AE0D-F36604E93B64Q34224973-72DC2BF4-A26B-4AEB-8B93-B25F47EF66F0Q34452244-2E415456-DB7A-4FFF-BA8A-E8AEA5B80B00Q34616642-7315FB7E-4515-4117-B964-FFF1E46E4E48Q34791209-E4E90E17-2676-49D6-ABEF-C0E0281248F8Q34990420-0EC20B3D-E365-435B-B773-BB601B7F7385Q35077892-68E05572-056F-4FEB-ABB7-A8F9EB174ECAQ35566601-AA41B0D4-7E69-43FF-AA8B-EC2738316E5BQ35690781-B379F46F-848E-4732-A88C-3A9DE7B99EE5Q35745343-7EC3A30F-080D-4BB3-9774-8A3AB1059F55Q35867712-E20DCD72-7216-4886-8679-B4E53C2D9507Q35887649-89C7C23D-4A27-4BCA-AEB5-72EEB842852DQ36256989-EC94F5A1-E133-4F0E-B264-17DF28D8354EQ36281893-BA372379-6225-46F2-B53E-9B544FA328FFQ36363325-A0EA2B6C-D68F-4A23-A269-90EC5A9B718FQ36937656-0875E803-87DD-4C1D-AA86-4C9EF43A584EQ37328584-74B7B7FC-43A8-44FC-B5C0-FBCC78F39021Q37415410-72EA52EB-EE5F-460A-AB08-2927440BC32DQ38008607-D408D911-1FC3-4148-9EBF-90FFE11467B2Q38068469-0482D6CB-0ADE-43B1-8952-4BC7F3D54DA4Q38079432-D9DCE0A7-4641-4BF8-81C1-A835098FF43EQ38130514-37E2D640-49D2-45AD-A309-E216B15897EDQ38172045-076FBBF4-A013-4A3F-B114-0FF2AFA3E356Q38604787-B5B871F6-FA9B-4279-97E6-41D4C20B2A21Q38617302-23FCA1B4-B120-4FE7-8910-26AB29446AD3Q38885776-A9DB96BB-3C76-445F-BEEF-3D9A538CED9FQ40065136-B8F6F104-B8D1-4934-B77E-9CBB624299EDQ40163890-9E62BD47-20FE-4630-8640-47EDE3277658Q40355982-7B1175D8-7A04-4EEB-9691-9706ED3FF222Q40796422-A319BCAB-07F1-450D-972A-692D2E44501CQ40812866-152D05BC-9697-4D08-9B10-2EFE2CE8CE13Q42138587-69CD2ECB-B710-4B3B-B33B-E28851DC8926Q42203587-35FB3CA0-4C99-466B-AB26-4B014BFAC206Q42346865-B277D783-6140-4D44-8566-FBF708B661D9Q45338183-4EA8B52E-4FB6-466F-B17D-6A0AA3633D26Q55079643-F01DD3F1-A375-4A95-B7CF-600A27D224D8Q56893551-9B872172-E747-4B5B-99E0-6D1EA594800AQ56894869-20C4D088-2157-46AF-85E1-DD4A3BB3A377
P2860
Assembly and immunological properties of Newcastle disease virus-like particles containing the respiratory syncytial virus F and G proteins.
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Assembly and immunological pro ...... cytial virus F and G proteins.
@ast
Assembly and immunological pro ...... cytial virus F and G proteins.
@en
Assembly and immunological pro ...... cytial virus F and G proteins.
@nl
type
label
Assembly and immunological pro ...... cytial virus F and G proteins.
@ast
Assembly and immunological pro ...... cytial virus F and G proteins.
@en
Assembly and immunological pro ...... cytial virus F and G proteins.
@nl
prefLabel
Assembly and immunological pro ...... cytial virus F and G proteins.
@ast
Assembly and immunological pro ...... cytial virus F and G proteins.
@en
Assembly and immunological pro ...... cytial virus F and G proteins.
@nl
P2093
P2860
P356
P1433
P1476
Assembly and immunological pro ...... cytial virus F and G proteins.
@en
P2093
Evelyn A Kurt-Jones
Gale Smith
Kathryn A Gravel
Lori W McGinnes
Madelyn R Schmidt
Michael J Massare
Robert W Finberg
Trudy G Morrison
P2860
P304
P356
10.1128/JVI.01861-10
P407
P577
2010-10-27T00:00:00Z